Greater efficacy of the ECMS-oil adjuvant over other formulations on immune responses against Bordetella bronchiseptica in rabbits and the underlying mechanism
Greater efficacy of the ECMS-oil adjuvant over other formulations on immune responses against Bordetella bronchiseptica in rabbits and the underlying mechanism
复制标题
与其他制剂相比，ECMS 油佐剂对家兔抗支气管败血博德特氏菌的免疫反应具有更强的功效及其潜在机制
DOI：
10.1016/j.intimp.2016.06.001
复制
发表时间：
2016-09-01
影响因子：
5.6
通讯作者：
Pan, Lijun
中科院分区：
文献类型：
--
作者：
Xiao, Chenwen;Bao, Guolian;Pan, Lijun
本研究评估了木鳖子提取物ECMS+油、单独油、单独ECMS、常规明矾佐剂对灭活支气管败血博德特氏菌(Bb)疫苗或仅使用抗原而无佐剂的对照的佐剂效果及其潜在机制。实验A的结果表明，在第21天，ECMS800μg+油组的Bb全细胞蛋白中的抗体水平显着高于其他佐剂组（p<0.05）。在第37天，凝集抗体滴度也高于其他组（p<0.05）。与其他佐剂组相比，ECMS800μg+油组改善了细胞免疫应答，包括仅使用抗原而不使用佐剂的对照和PBS 组（p < 0.05）。 Bb攻击后，ECMS800μg+油组表现出最高的保护率，显着高于单独ECMS或单独使用抗原而无佐剂的对照以及PBS组(p<0.05和p<0.01)。 ECMS800μg+油组中的IgA细胞与肺中其他组的IgA细胞显着不同（p<0.01）。细胞招募结果显示，ECMS400μg+油中的淋巴细胞数量高于除ECMS(100μg/800μg)+油组之外的其他组中的细胞数量(p<0.05)。 ECMS(100μg/400μg)+油组中的中间细胞数高于其他组的细胞数，包括仅使用抗原组的对照(p<0.05)。 ECMS(100μg/400μg/800+油组)中性粒细胞显着高于ECMS 800μg和单独使用抗原的对照组(p<0.05)。ECMS100μg+油组中的白细胞显着高于油、ECMS800μg和单独使用抗原的对照组(p<0.05)。ECMS800μg+油组中IL-2的表达除ECMS400μg+油组外，ECMS800μg+油组中的IL-4表达显着高于其他组（p<0.05），ECMS800μg+油组中的GATA3显着高于仅使用抗原的ECMS-油佐剂组（p<0.05）。保护支气管败血芽孢杆菌免疫的兔子，因此可能是改善兔子支气管败血芽孢杆菌疫苗接种的另一种方法 (C) 2016 Elsevier B.V. 保留所有权利。
In this study, the adjuvant effects of the extract of Cochinchina momordica seed ECMS + oil, oil alone, ECMS alone, conventional alum adjuvant on inactivated Bordetella bronchiseptica (Bb) vaccine or control using antigen alone without adjuvant were evaluated along with the underlying mechanism. The results in experiment A demonstrated that antibody levels in Bb whole cell protein in the ECMS800 mu g + oil group were significantly higher than in the other adjuvant groups (p < 0.05) on day 21. The agglutination antibody titer was also higher than the other groups (p < 0.05) on day 37. The ECMS800 mu g + oil group improved cellular immune responses compared to other adjuvant groups, including control using antigen alone without adjuvant and the PBS group (p < 0.05). After Bb challenge, the ECMS800 mu g + oil group showed the highest protection rate, which was significantly higher than ECMS alone or control using antigen alone without adjuvant and the PBS group (p < 0.05 and p < 0.01). IgA cells in the ECMS800 mu g + oil group differed significantly from the IgA cells of other groups in the lungs (p < 0.01). The results of cell recruitment showed that the number of lymphocytes in the ECMS400 mu g + oil were higher than the number of cells for other groups except the ECMS(100 mu g/800 mu g) + oil groups (p < 0.05). Intermediate cells in the ECMS(100 mu g/400 mu g) + oil groups were higher than the number of cells for other groups, including the control using antigen alone group (p < 0.05). Neutrophils in the ECMS(100 mu g/400 mu g/800 + oil groups were significantly higher than the ECMS 800 mu g and control using antigen alone groups (p < 0.05). White blood cells in the ECMS100 mu g + oil group were significantly higher than the oil, ECMS800 mu g and control using antigen alone groups (p < 0.05). IL-2 expression in the ECMS800 mu g + oil group was significantly higher than other groups, except for the ECMS400 mu g + oil group (p < 0.05). IL-4 expression in the ECMS800 mu g + oil group was significantly higher than other groups (p < 0.05). GATA3 in the ECMS800 mu g + oil groups was significantly higher than the oil, ECMS800 mu g and control using antigen alone group (p < 0.05). ECMS-oil adjuvant mixture could most effectively protect B. bronchiseptica immunized rabbits and, therefore, could be an alternative way of improving B. bronchiseptica vaccination in rabbits. (C) 2016 Elsevier B.V. All rights reserved.